Thursday, July 24, 2014

Fwd: MMWR Vol. 63 / No. SS-7



---------- Forwarded message ----------
From: Centers for Disease Control & Prevention <cdc@service.govdelivery.com>
Date: Thu, Jul 24, 2014 at 10:25 AM
Subject: MMWR Vol. 63 / No. SS-7
To: iammejtm@gmail.com


Having trouble viewing this email? View it as a Web page.

Bookmark and Share

MMWR Logo
 
MMWR Surveillance Summaries
Vol. 63, No. SS-7
July 25, 2014
 
PDF
 

In this report

Prevalence of Amyotrophic Lateral Sclerosis — United States, 2010–2011
Paul Mehta, MD, Vinicius Antao, MD, Wendy Kaye, PhD, et al.
MMWR 2014;63(No. SS-7)


Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive and fatal neuromuscular disease for which no cure has been identified. In 2009, the federal Agency for Toxic Substances and Disease Registry (ATSDR) implemented the National ALS Registry to collect and analyze data regarding persons with ALS in the United States. During October 19, 2010–December 31, 2011, a total of 12,187 persons meeting the surveillance case definition of definite ALS were identified by the Registry, for a prevalence of 3.9 cases of ALS per 100,000 persons in the U.S. general population. Data collected by the National ALS Registry are being used to describe the prevalence of ALS in the United States better and to help facilitate research.

 
Department of Health and Human Services
Centers for Disease Control and Prevention

Modify/Update Subscriber Preferences  |  Unsubscribe  |  Send Feedback  |  Learn about CDC Updates

Questions or problems? Please contact support@govdelivery.com.

CDC 24/7 – Saving Lives, Protecting People, Saving Money. CDC.gov/24-7…Dept of Health and Human Services LogoHelp reduce the rates in your state.  Learn more.
CDC on Facebook   CDC on Twitter   CDC YouTube Channel  

This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta, GA 30333 · 1-800-CDC-INFO (800-232-4636) Powered by GovDelivery



--
Jeremy Tobias Matthews

No comments:

Post a Comment